CN113924315A - 抗β-NGF纳米抗体及其应用 - Google Patents

抗β-NGF纳米抗体及其应用 Download PDF

Info

Publication number
CN113924315A
CN113924315A CN202080000967.3A CN202080000967A CN113924315A CN 113924315 A CN113924315 A CN 113924315A CN 202080000967 A CN202080000967 A CN 202080000967A CN 113924315 A CN113924315 A CN 113924315A
Authority
CN
China
Prior art keywords
seq
nanobody
ngf
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080000967.3A
Other languages
English (en)
Other versions
CN113924315B (zh
Inventor
刘红
宋德勇
邢平平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Boan Biotechnology Co Ltd
Original Assignee
Shandong Boan Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Boan Biotechnology Co Ltd filed Critical Shandong Boan Biotechnology Co Ltd
Publication of CN113924315A publication Critical patent/CN113924315A/zh
Application granted granted Critical
Publication of CN113924315B publication Critical patent/CN113924315B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Abstract

提供一种结合β‑NGF 抗原的纳米抗体或多价纳米抗体，可用于治疗、预防、检测或诊断与β‑NGF 相关的疾病，如疼痛或炎症，尤其是手术后疼痛、类风湿性关节炎痛及骨关节炎疼痛中的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080000967.3A 2019-06-10 2020-06-08 抗β-NGF纳米抗体及其应用 Active CN113924315B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910497627 2019-06-10
CN2019104976275 2019-06-10
CN201910498443 2019-06-10
CN2019104984430 2019-06-10
PCT/CN2020/094938 WO2020248942A1 (zh) 2019-06-10 2020-06-08 抗β-NGF纳米抗体及其应用

Publications (2)

Publication Number Publication Date
CN113924315A true CN113924315A (zh) 2022-01-11
CN113924315B CN113924315B (zh) 2022-06-28

Family

ID=73780661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080000967.3A Active CN113924315B (zh) 2019-06-10 2020-06-08 抗β-NGF纳米抗体及其应用

Country Status (2)

Country Link
CN (1) CN113924315B (zh)
WO (1) WO2020248942A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112961244B (zh) * 2021-02-28 2023-08-29 熙源安健医药（上海）有限公司 抗TrkA抗体或其抗原结合片段、其制备方法和应用
CN116063529B (zh) * 2021-12-29 2023-09-26 华道(上海)生物医药有限公司 一种抗间皮素的高亲和力纳米抗体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077441A1 (en) * 2005-01-24 2006-07-27 Cambridge Antibody Technology Limited Specific binding members for ngf
CN101014364A (zh) * 2002-12-24 2007-08-08 里纳特神经系统学公司 抗ngf抗体及其使用方法
US20080182978A1 (en) * 2002-12-24 2008-07-31 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
WO2009023540A1 (en) * 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US20180016331A1 (en) * 2010-12-01 2018-01-18 Alderbio Holdings Llc Methods of preventing or treating pain using anti-ngf antibodies
CN108178798A (zh) * 2016-12-08 2018-06-19 苏州方德门达新药开发有限公司 pH工程化的NGF抗体及其医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
ES2514319T3 (es) * 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
WO2012075340A2 (en) * 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9617334B2 (en) * 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014364A (zh) * 2002-12-24 2007-08-08 里纳特神经系统学公司 抗ngf抗体及其使用方法
US20080182978A1 (en) * 2002-12-24 2008-07-31 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
CN102746399A (zh) * 2002-12-24 2012-10-24 里纳特神经系统学公司 抗ngf抗体及其使用方法
WO2006077441A1 (en) * 2005-01-24 2006-07-27 Cambridge Antibody Technology Limited Specific binding members for ngf
CN101107268A (zh) * 2005-01-24 2008-01-16 剑桥抗体技术有限公司 针对ngf的特异性结合成员
US20130302325A1 (en) * 2005-04-11 2013-11-14 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
WO2009023540A1 (en) * 2007-08-10 2009-02-19 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
CN101827609A (zh) * 2007-08-10 2010-09-08 里珍纳龙药品有限公司 抗人神经生长因子的高亲和力人抗体
US20120164688A1 (en) * 2007-08-10 2012-06-28 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US20180016331A1 (en) * 2010-12-01 2018-01-18 Alderbio Holdings Llc Methods of preventing or treating pain using anti-ngf antibodies
CN108178798A (zh) * 2016-12-08 2018-06-19 苏州方德门达新药开发有限公司 pH工程化的NGF抗体及其医药用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
L.XU等: "The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain.", 《OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL》 *
LAICHE DJOUHRI: "PG110,A Humanized Anti-NGF Antibody,Reverses Established Pain Hypersensitivity in Persistent Inflammatory Pain,but not Peripheral Neuropathic Pain,Rat Models.", 《PAIN MEDICINE》 *
XIAO JUN LIU等: "Purification and Bioassay of Mouse β NGF Antibody", 《JOURNAL OF CHINESE PHARMACEUTICAL SCIENCES》 *
陆艳红: "抗人神经生长因子（NGF）单克隆抗体的研制及生物学特性的研究", 《中国优秀硕士论文全文数据库 医药卫生科技辑》 *

Also Published As

Publication number Publication date
CN113924315B (zh) 2022-06-28
WO2020248942A1 (zh) 2020-12-17

Similar Documents

Publication Publication Date Title
US11292841B2 (en) Anti-PD-1 nano-antibody and application thereof
US20220002418A1 (en) Anti-pd-l1/vegf bifunctional antibody and use thereof
CN109937212B (zh) B7-h3抗体、其抗原结合片段及其医药用途
CN108409860B (zh) 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
CN112166121B (zh) 神经生长因子的单克隆抗体及其编码基因和应用
CN111533805B (zh) 一种抗癌胚抗原的高亲和力纳米抗体及其应用
JP7236562B2 (ja) インターロイキン－４受容体抗体及びその用途
WO2016173558A1 (zh) 抗诺如病毒gii.4型鼠源单克隆抗体的制备和应用
CN113924315B (zh) 抗β-NGF纳米抗体及其应用
CN109897107B (zh) 纳米抗体及其制备方法
CN116178541A (zh) 抗ngf抗体及其抗原结合片段、其制备方法和应用
CN113101364A (zh) 一种自免疫抑制剂的开发和应用
CN108635579B (zh) 抗人bFGF纳米抗体在制备治疗黑色素瘤药物中的应用
EA026119B1 (ru) Новое антитело против рецептора il-23 человека
CN117264068A (zh) 抗TrkA抗体或其抗原结合片段、其制备方法和应用
WO2019238074A1 (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
CN110423274B (zh) 抗绿脓杆菌外毒素a纳米抗体及其应用
JP2008515390A (ja) ニューモリシンに対する結合メンバー
CN111065651B (zh) Il-5抗体、其抗原结合片段及医药用途
CN114516917B (zh) 人源化抗TrkA的抗体及其应用
CN112062848B (zh) 抗cd47单克隆抗体及其应用
WO2023035272A1 (zh) 一种il17抗体及其制备方法和应用
CN114920838B (zh) 一种抗il-17a的单域抗体及其用途
KR101510831B1 (ko) 항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제
WO2022141378A1 (zh) 一种抗pd-1的单域抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant